Effects of two new α-glucosidase inhibitors on glycemic control in patients with insulin-dependent diabetes mellitus
✍ Scribed by Dimitriadis, G. ;Raptis, S. ;Raptis, A. ;Hatziagelaki, E. ;Mitrakou, A. ;Halvatsiotis, P. ;Ladas, S. ;Hillebrand, I.
- Publisher
- Springer-Verlag
- Year
- 1986
- Tongue
- English
- Weight
- 593 KB
- Volume
- 64
- Category
- Article
- ISSN
- 1432-1440
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Of 23 patients with non-insulin-dependent diabetes mellitus (NIDDM), whose fasting blood glucose had not reached less than or equal to 6.0 mmol.l-1 after 10 weeks of dietary regulation, 15, who had had a weight reduction of -2.8 kg by dietary control, did achieve a fasting blood glucose less than or
In a double-blind, randomized study, miglitol (BAY m 1099), an ␣-glucosidase inhibitor, 100 mg tds or placebo was given orally with meals for a period of 24 weeks in 117 patients with Type 2 (non-insulin-dependent) diabetes mellitus (DM) treated with insulin. Fasting and 1 h postprandial plasma gluc
We have studied the absorption of glibenclamide 10 mg as a single morning dose in 7 patients with non-insulin-dependent diabetes mellitus, comparing normoglycaemic and hyperglycaemic states. The maximal glibenclamide plasma concentrations were significantly higher in the normoglycaemic than in the h